Cover Image

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Brain metastases are detectable in 25-35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of...

Full description

Saved in:
Bibliographic Details
Main Authors: G. A. Dashyan (Author), V. F. Semiglazov (Author), P. V. Krivorot'ko (Author), T. Yu. Semiglazova (Author), E. E. Topuzov (Author), R. M. Paltuev (Author), K. Yu. Zernov (Author), V. S. Apollonova (Author), S. S. Ereshchenko (Author), A. V. Petrova (Author), E. K. Zhil'tsova (Author), O. A. Ivanova (Author)
Format: Book
Published: ABV-press, 2016-06-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Brain metastases are detectable in 25-35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of investigations substantiating the use of anti-HER-2 targeting agents, as well as the innovative agent T-DM1 to treat brain metastases.
Item Description:1994-4098
1999-8627
10.17650/1994-4098-2016-12-1-46-51

Similar Items